A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M(1) receptor agonist HTL0018318 in patients with mild‐to‐moderate Alzheimer's disease

INTRODUCTION: This study examined the safety and pharmacodynamic effects of selective muscarinic M(1) receptor orthosteric agonist HTL0018318 in 60 patients with mild‐to‐moderate Alzheimer's disease (AD) on background donepezil 10 mg/day. METHODS: A randomized, double‐blind, placebo‐controlled...

Descripción completa

Detalles Bibliográficos
Autores principales: Nathan, Pradeep J., Millais, S. Babli, Godwood, Alex, Dewit, Odile, Cross, David M., Liptrot, Janet, Ruparelia, Bharat, Jones, Stephen Paul, Bakker, Geor, Maruff, Paul T., Light, Gregory A., Brown, Alastair J.H., Weir, Malcolm Peter, Congreve, Miles, Tasker, Tim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864442/
https://www.ncbi.nlm.nih.gov/pubmed/35229025
http://dx.doi.org/10.1002/trc2.12273

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864442/
https://www.ncbi.nlm.nih.gov/pubmed/35229025
http://dx.doi.org/10.1002/trc2.12273

Ejemplares similares